Skip to main content

& Events


No events scheduled at this time.

Press Releases

January 17, 2024

Comanche Biopharma Closes Oversubscribed $75 Million Series B Financing to Advance Mission to Develop and Make Globally Available the First Treatment Targeting a Root Cause of Preeclampsia

August 28, 2023

Comanche Biopharma Named by Fierce Biotech as a “Fierce 15” Biotech Company of 2023

August 23, 2023

Comanche Biopharma Receives US FDA Fast Track Designation for CBP-4888 for the Treatment of sFlt-1 mediated pre-term preeclampsia

June 13, 2023

Comanche Biopharma Strengthens Board of Directors with Appointment of Dr. Ann Taylor

May 12, 2023

Comanche Biopharma Appoints Allyson Felix to Board of Directors

March 30, 2023

Comanche Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for CBP-4888, an siRNA Investigational Therapy for the Treatment of Preeclampsia

December 15, 2022

Comanche Biopharma Announces Appointment of Allison August, M.D., as Chief Medical Officer

Media Contact

Liz Melone
Melone Communications, LLC
Mobile: +1 617-256-6622

Contact Us

50 Beharrell St, Unit B
Concord, MA 01742

Contact Us

Comanche is a biopharmaceutical company developing an investigational siRNA medicine for preterm preeclampsia. We envision a world where all women and their babies have access to safe and effective therapies for treating life threatening complications of pregnancy, and those solutions must be evidence-based and affordable.

Sign up to receive email updates

Translate 🌎 💬